TDACU Translational Development Acquisition Corp.

Price Chart

Executive Summary

Translational Development Acquisition Corp. (TDACU) filed Amendment No. 2 to its 2025 10-K in response to an SEC comment letter. The sole purpose is to revise the conclusion on disclosure controls and procedures from effective to not effective as of December 31, 2025, and to file new SOX certifications. This is a negative signal for a blank-check company still seeking a business combination, as it indicates the SEC found the prior controls assessment inadequate.

Actionable Insight

Key Facts

• Amendment filed in response to SEC comment letter dated May 7, 2026 regarding Amendment No. 1
• Company revised Item 9A to conclude disclosure controls and procedures were NOT effective as of December 31, 2025
• Management still asserts internal control over financial reporting was effective
• New SOX Section 302 and 906 certifications filed as Exhibits 31.1, 31.2, 32.1, 32.2
• Company is a shell company (blank check) with no operating business, seeking a business combination
• Market value of public float as of June 30, 2025: $177,675,000
• 17,250,000 Class A shares and 4,657,500 Class B shares outstanding as of March 30, 2026

Financial Impact

No financial restatement; the amendment only revises the controls conclusion and adds certifications. However, the admission of ineffective disclosure controls raises regulatory and litigation risk for a SPAC that has not yet completed a de-SPAC transaction.

Risk Factors

• SEC enforcement action or additional comment letters
• Inability to complete a de-SPAC transaction due to control deficiencies
• Shareholder litigation or increased redemption rates
• Potential Nasdaq delisting if reporting issues persist

Market Snapshot

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

US Market Status

Related Tickers